31 results about "Cellular Immunology" patented technology

The present invention relates to a method for diagnosing Lyme disease in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of Borrelia antigens and (c) determining the expression level of a pro-inflammatory cytokine in said sample at the end of step (b).

The invention provides a cellular immunological detection kit for evaluating the curative effect of a vaccine and a storage method thereof. The kit comprises MHC-restricted antigen peptide. The cellular immunological detection kit for evaluating the curative effect of the vaccine can utilize a therapeutic vaccine research database and specimens in a clinic trial phase and employs flow cytometry for comprehensive detection of immune cells and cytokines secreted by the immune cells, so a cellular immunological curative effect evaluation system is established. The cellular immunological detection kit for evaluating the curative effect of the vaccine has good stability, and the stability can maintain 90% or above after for storage for one year or above.

The invention belongs to the technical field of cellular immunology, in particular to a method for amplifying human peripheral blood gamma / deltaT cells massively and preferentially in vitro. The method comprises the following steps of: (1) preparing tubercle bacillus heat stable antigen by using the cultured tubercle bacillus; (2) stimulating to amplify the gamma / deltaT cells by combining the prepared tubercle bacillus heat stable antigen and cell factors rhIL-2 and rhIL-21; and (3) performing morphologic observation through a microscope, performing purity and immunophenotyping analysis by using a flow cytometry, and performing cytotoxicity detection through MTT assay. The method has the advantages that: culture conditions and operation are simple, a large number of gamma / deltaT cells with high purity and high cytotoxicity can be prepared in short time, and the cost is low.

The invention belongs to the technical field of cellular immunology, and particularly relates to a morphology and purity and immunophenotyping detection method of human (gamma)(delta)T cells, which is used for detecting the prepared human (gamma)(delta)T cells. The method comprises the following steps: preparing human (gamma)(delta)T cells; and performing morphological observation with a microscope and purity and immunophenotyping analysis with a flow cytometer. The method provided by the invention has the advantages that the (gamma)(delta)T cells obtained by the test have the characteristics of large quantity, high purity, strong cytotoxicity and the like so as to ensure that the prepared human (gamma)(delta)T cells can meet the clinical needs; and moreover, the effects that the culture cost is greatly reduced from the non-peptide phosphate antigens such as IPP and the irritants such as anti-TCR (gamma)(delta) antibody are realized and the problems of small quantity, low toxicity, high cost and the like of in-vitro culture of (gamma)(delta)T cells in the prior art are solved.

The invention relates to the field of biotechnology, and discloses a virus-specific target and application thereof. The hepatitis B virus specific target amino acid sequence of the present invention is FCWEWASAK. The present invention also provides the application of the target in the preparation of preparations for treating diseases related to hepatitis B. The target of the present invention can realize the effective expansion and activation of dendritic cells in vitro, and the presented T lymphocytes have a specific killing effect on the virus, which is currently the most cellular immunotherapy technology in line with the principle of cellular immunology, and has the advantages of Good application prospects.

The invention relates to the technical field of biology, and discloses a tumor specific target and application thereof. The target amino acid sequence is SAKYGVRKF. The tumor specific target can implement extraneous effective amplification and activation of dendritic cells. The provided T lymphocyte has specific killing effects on tumors, and is a cellular immunotherapy technique which most conforms to the cellular immunology principle at present.

The invention belongs to the field of cellular immunology, and discloses a methodological study for inducing mass generation of dendritic cells (DCs) from cord blood CD34+ hematopoietic stem cells. The method comprises the following main steps: separating mononuclear cells from cord blood, separating CD34+ hematopoietic stem cells through an immunomagnetic bead positive screening method, continuously amplifying the CD34+ cells for 30 days by using an amplification culture medium (IMDM, FBS, GM-CFS, SCF), periodically collecting mass CD34-DC precursor cells during the amplification process, and inducing the precursor cells to be differentiated into immaturate DCs through a GM-CFS / IL-4 culture medium. The method disclosed by the invention is capable of obtaining the DCs with 109 orders of magnitudes; compared with the traditional DCs induced by peripheral blood mononuclear cells, the CD34-DCs have high antigen phagocytic capacity and the capacity of inducing T lymphocyte proliferation.

The present invention relates to a method for diagnosing Q-fever in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of a Coxiella burnetii antigen and (c) determining the expression level of a pro-inflammatory cytokine such as IFN-γ in said sample at the end of step (b).

The invention belongs to the technical field of cellular immunology, and particularly relates to a method for detecting the killing activity of human (gamma)(delta)T cells against a K562 cell strain, which is used for detecting the prepared human (gamma)(delta)T cells. The method comprises the following steps: preparing the human (gamma)(delta)T cells; fetching the K562 cell strains of the logarithmic phase as target cells, and adjusting the cell density to 1*10<5> / ml, 5*10<4> / ml and 2.5*10<4> / ml; paving the target cells in a 96-hole culture plate with 100mu l per hole, and culturing for 24 hours; fetching the prepared human (gamma)(delta)T cells, and adjusting the cell density to 1*10<6>ml; adding the human (gamma)(delta)T cells into the 96-hole culture plate, wherein the effect-target ratios are 10:1, 20:1 and 40:1 respectively; and setting 3 parallel holes for each density, setting blank controls respectively and calculating the killing activity. By adopting the method provided by the invention, the toxicity of the human (gamma)(delta)T cells is guaranteed.